The European Investment Bank has invested €75 million in a risk-sharing drug development deal with the pharmaceutical company UCB, potentially opening up a new source of research and development (R&D) funding.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Drug repurposing: a systematic review on root causes, barriers and facilitators
BMC Health Services Research Open Access 29 July 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Bank tests drug development waters. Nat Rev Drug Discov 13, 643–644 (2014). https://doi.org/10.1038/nrd4412
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4412
This article is cited by
-
Drug repurposing: a systematic review on root causes, barriers and facilitators
BMC Health Services Research (2022)